Tags : Novo Nordisk

PharmaShots Weekly Snapshot (Aug 17 -21 2020)

1. BioMarin Reports NDA Submission to the US FDA for Vosoritide to Treat Children with Achondroplasia Published: Aug 20, 2020 | Tags:  BioMarin, Reports, NDA, Submission, US, FDA, Vosoritide, Children, Achondroplasia 2. Junshi and Impact to Establish Joint Venture for Senaparib (IMP4297) in China Published: Aug 20, 2020 | Tags:  Junshi, Impact, Establish, Joint Venture, […]Read More

Novo Nordisk Collaborates with Evotec to Develop Therapies Targeting Chronic

Shots: Evotec to receive $179M/ product as upfront, research funding and milestones along with the royalties on sales of the therapies while Novo Nordisk will lead the clinical development and commercialization of the therapies The companies will share responsibilities during drug discovery and pre-clinical development and will jointly identify and develop novel targets based on […]Read More

Novo Nordisk Resumes P-III Study of Concizumab for Patients with

Shots: The company resumes the P-III program (explorer6, 7, and 8) of concizumab. The clinical trials are evaluating concizumab (SC) prophylaxis treatment in hemophilia A and B patients regardless of their inhibitor status The trials will be resumed as soon as local procedures allow. This follows pausing of the trials in Mar’20 due to the […]Read More

Top 20 Prescription Drugs Based on 2019 Revenue

The average life expectancy span of Human Beings are increased due to better medical facilities and drugs developed by Biopharma companies. Pharmaceutical products or drugs or medicines are being produced for a wide range of medical sectors. It includes the lifesaving drugs or the major therapy area including immunology, cardiology, and neurology but are they […]Read More

PharmaShots Weekly Snapshot (Jun 08- 12, 2020)

 1. Medtronic Receives CE Mark for MiniMed 780G Insulin Pump to Treat Type 1 Diabetes                                                Published: Jun 11, 2020 | Tags: Medtronic, Receives, CE, Mark, MiniMed 780G, Insulin Pump, Treat, Type 1 Diabetes 2.  Takeda to Divest OTC and Select Non-core Assets to Celltrion for ~ $278M        Published: Jun 11, 2020 | Tags: Takeda, Divest, [&Read More

Novo Nordisk to Acquire AstraZeneca’s Spin-off Corvidia for ~$2.1B

Shots: Novo Nordisk to acquire in all-cash transaction, making a total deal value ~$2.1B which included $725M as upfront and a remaining as regulatory and sales milestones The acquisition of Corvidia Therapeutics along with its lead candidate, ziltivekimab allow the Novo Nordisk to expand its footprints across cardiometabolic diseases Ziltivekimab is a fully human mAb […]Read More

Top 20 BioPharma Companies based on 2019 Total Revenue

The global biopharma companies are developing novel therapies & devices which is, in turn, enhancing their portfolio and encouraging them in this undergoing competition to stay in the topmost position. The top 20 companies’ chartbusters changed their 2019 ranking, but the history of Johnson and Johnson did not change and it continued being at the […]Read More

PharmaShots Weekly Snapshot (March 16-20, 2020)

1. Merck Collaborates with Dragonfly to Develop and Commercialize Novel Therapies Utilizing TriNKET Platform Published: Mar 19, 2020 | Tags: Merck, Collaborates, Dragonfly, Develop, Commercialize, Novel Therapies, Utilizing, TriNKET Platform 2.  BGI Reports the Availability of RT-PCR SARS-CoV-2 Test for Clinical Use in the US Published: Mar 20, 2020 | Tags: BGI, Reports, Availability, RT-PCR, SARS-CoV-2 […]Read More

Novo Nordisk Halts Clinical Studies Evaluating Concizumab (anti-TFPI mAb) for

Shots: Novo Nordisk has paused its two P-III clinical studies (explorer7 and 8) and one P-II clinical study (explorer5) investigating concizumab prophylaxis treatment in hemophilia A and B patients regardless of inhibitor status The studies have been paused due to the occurrence of non-fatal thrombotic events in three patients enrolled in the ongoing P-III program. […]Read More